ATMP XB, a collaborative Interreg initiative

OHMX.bio is partner in the EU co-funded ATMP XB project, aiming to strengthen the Flemish- Dutch border region as a leading hub for ATMPs. Through collaboration between educational institutions, hospitals and companies, ATMP XB focuses on improving production, quality control, technology development and specialized training to help bring these innovative therapies to patients faster and more safely.
OHMX.bio is contributing to ATMP XB, a collaborative Interreg initiative aimed at strengthening the QA/QC ecosystem for Advanced Therapy Medicinal Products (ATMPs) in the Flemish-Dutch border region.

Cell and gene therapies are transforming modern medicine, but their personalized nature introduces complex challenges in quality control, sterility testing, and manufacturing reliability. ATMP XB brings together leading academic, clinical, and industry partners to address these challenges through a networked competence center focused on QA/QC innovation.

By increasing testing capacity, facilitating collaboration between stakeholders, and supporting developers with targeted expertise, the project helps accelerate the development of safe and effective advanced therapies.

The insights generated within the project will also contribute to training initiatives aimed at strengthening the ATMP workforce and expertise within the region.

ATMP XB is cofunded by the European Union under Interreg Vlaanderen-Nederland. The project is led by Biovia and involves POM Antwerpen, at.las ATMP, Smart BioMaterials Center (SBMC), anicells, IDEVAX, QbD Group, Karel de Grote-Hogeschool, UZ Gent, Anabiotec, RegMed XB, Sure Laboratories – Trust us to be Sure.
Interreg logo_ATMP XB_Positief

Search all posts

Popular news & events

Knowledge-for-Growth-2026_OHMX.bio

Tags

Do you have questions about ATMP XB?

Fill out the form below and our experts will get back to you as soon as possible!

Search all posts

Popular news & events

Tags